GSK: EU approval for HIV prevention
(CercleFinance.com) - GSK, through ViiV Healthcare, has announced that the European Commission has authorised Apretude (long-acting (LA) cabotegravir injection and tablets) for HIV prevention.
ViiV Healthcare is a global HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,
Cabotegravir is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents (aged at least 12 years) weighing at least 35 kg.
Copyright (c) 2023 CercleFinance.com. All rights reserved.